New generation combination product companies left high and dry by FDA
This article was originally published in Clinica
Executive Summary
The FDA needs to draft guidance in the next year or two on what procedures companies should follow if they want to modify combination products, the Regulatory Affairs Professionals Society (RAPS) decided during a two-day consensus summit in Baltimore, Maryland, last week.